US Stock MarketDetailed Quotes

ARWR Arrowhead Pharmaceuticals

Watchlist

22.330
-0.280-1.24%

Close Apr 19 16:00 ET

22.330
+0.000+0.00%

Post 17:53 ET

2.77BMarket Cap-8061P/E (TTM)

Arrowhead Pharmaceuticals Stock Forum

stockhub

Apr 7 11:23

Hope price action is consistent with result

Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia
$Arrowhead Pharmaceuticals(ARWR.US)$

Mooers' Insights

Tonyco

Apr 6 22:01

$Arrowhead Pharmaceuticals(ARWR.US)$
Insiderd selling shares and financials dont look good. Im guessing they dont have anything in the pipeline?

Moomoo AI

Mar 8 05:54

The company's poor performance and the CEO's high pay, despite falling earnings and shareholder value, may upset shareholders. The upcoming AGM on March 14th is a chance for shareholders to hold the board and management accountable.

We Think Shareholders May Want To Consider A Review Of Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

zulia3003

Mar 7 11:34

$Arrowhead Pharmaceuticals(ARWR.US)$ why drop today?

AuthPresidentColor8c

Mar 1 10:33

$Arrowhead Pharmaceuticals(ARWR.US)$ such a odd spot here

ApextradezCOM

Feb 25 15:54

PH.2 Results + ER Win =🚀

$Celldex Therapeutics(CLDX.US)$
$Arrowhead Pharmaceuticals(ARWR.US)$ - Alpha Early Alert 🚨 H&S 📈🎯🚀🥇 (45.00) is on the Table 🫵🏻💪🏻🥇 Find the Apex and win!

Moomoo AI

Jan 4 06:44

The company's P/S ratio is high in contrast to its lower projected growth, a divergence that could bring risk to shareholders and potential investors. The current P/S ratio might not sustain due to predicted future revenues.

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 36% But Its Business Is Yet to Catch Up

Moomoo AI

Dec 14, 2023 09:54

High level of risk for Arrowhead Pharmaceuticals with negative EBIT and a dip in free cash flow. The company burnt US$331m, reported a US$205m loss raising capital raising flags. Investors monitor balance sheet and warning signs needed.

Health Check: How Prudently Does Arrowhead Pharmaceuticals (NASDAQ:ARWR) Use Debt?

Moomoo AI

Nov 23, 2023 04:30

Javier San Martin's insider sale at current price level is not a major concern, nor a positive sign. The lack of insider buying over the past year and mediocre level of insider ownership warrant caution in purchasing its stock.

Arrowhead Pharmaceuticals Chief Medical Officer Javier San Martin Sells 36% Of Holding

ilovemoney29

Jan 6, 2023 04:46

$Arrowhead Pharmaceuticals(ARWR.US)$ Presenting P2 results +p3 design on monday during JPM healthcare conference, first one to present on prime monday.

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall